Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Sega

Showing results (1-10 of 60) with videos related to

Pageof 6
Sort By:
Blood Pressure|August 18, 1999
Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study GroupR Sega
Giornale Italiano Di Medicina Del Lavoro Ed Ergonomia|October 30, 2003
[Stress, socio-occupational factors and cardiovascular risk: Italian experience]G Cesana, M Ferrario, R Sega
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1991
Lessons from the MONICA study in northern ItalyM Ferrario, R Sega, G Cesana
Respiration; International Review of Thoracic Diseases|January 1, 1979
Respiratory response to carbon dioxide after propranolol in normal subjectsE Bosisio, M Sergi, R Sega, et al.
Giornale Italiano Di Cardiologia|January 1, 1979
[Long term treatment with acebutolol in hypertension (author's transl)]R Fogari, R Jemoli, S Del Mastro, et al.
Journal of Pharmacokinetics and Biopharmaceutics|June 1, 1977
Pharmacokinetics of propranolol in normal healthy volunteersR Gomeni, G Bianchetti, R Sega, et al.
La Medicina Del Lavoro|March 1, 1985
[Socio-occupational factors and coronary disease]G C Cesana, M Ferrario, R Zanettini, et al.
American Journal of Hypertension|June 1, 1993
Ambulatory blood pressure monitoring in the design of studies on antihypertensive drug efficacyG Mancia, S Omboni, G Parati, et al.
Respiration; International Review of Thoracic Diseases|January 1, 1985
Ventilatory response to carbon dioxide and to isometric muscle contraction after administration of placebo, propranolol, mepindolol and salbutamolE Bosisio, F Colombo, R Sega, et al.
Bollettino Chimico Farmaceutico|August 1, 1978
[Intersubject comparison of the bioavailability of spironolactone in 2 pharmaceutical dosage forms]P D Lucchelli, A Monarca, S Del Mastro, et al.
Pageof 6

Showing results (1-10 of 60) with videos related to

Sort By:
Pageof 6
Blood Pressure|August 18, 1999
Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study GroupR Sega
Giornale Italiano Di Medicina Del Lavoro Ed Ergonomia|October 30, 2003
[Stress, socio-occupational factors and cardiovascular risk: Italian experience]G Cesana, M Ferrario, R Sega
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1991
Lessons from the MONICA study in northern ItalyM Ferrario, R Sega, G Cesana
Respiration; International Review of Thoracic Diseases|January 1, 1979
Respiratory response to carbon dioxide after propranolol in normal subjectsE Bosisio, M Sergi, R Sega, et al.
Giornale Italiano Di Cardiologia|January 1, 1979
[Long term treatment with acebutolol in hypertension (author's transl)]R Fogari, R Jemoli, S Del Mastro, et al.
Journal of Pharmacokinetics and Biopharmaceutics|June 1, 1977
Pharmacokinetics of propranolol in normal healthy volunteersR Gomeni, G Bianchetti, R Sega, et al.
La Medicina Del Lavoro|March 1, 1985
[Socio-occupational factors and coronary disease]G C Cesana, M Ferrario, R Zanettini, et al.
American Journal of Hypertension|June 1, 1993
Ambulatory blood pressure monitoring in the design of studies on antihypertensive drug efficacyG Mancia, S Omboni, G Parati, et al.
Respiration; International Review of Thoracic Diseases|January 1, 1985
Ventilatory response to carbon dioxide and to isometric muscle contraction after administration of placebo, propranolol, mepindolol and salbutamolE Bosisio, F Colombo, R Sega, et al.
Bollettino Chimico Farmaceutico|August 1, 1978
[Intersubject comparison of the bioavailability of spironolactone in 2 pharmaceutical dosage forms]P D Lucchelli, A Monarca, S Del Mastro, et al.
Pageof 6